Glossary
- Ablation
- Abscopal
- Active surveillance
- Active surveillance
- Acute
- Adenoma
- Adenopathy
- Adherence
- Adjunct therapy
- Adjuvant therapy
- Adrenalectomy
- Adrenal gland
- Advanced cancer
- Adverse event
- Aetiological study
- Afinitor
- AGS-003
- AJCC Staging System
- Allogenic stem cell transplantation
- Alternative medicine
- Analgesic
- Anaplastic
- Anemia
- Angiogenesis
- Angiogenesis inhibitor
- Anorexia
- Anti-angiogenic agents
- Antibody
- Antibody therapy
- Anti- emetic
- Antigen
- Apoptosis
- Arterial embolisation
- Ascities
- Assisted robotic surgery
- Asymptomatic
- Atezolizumab
- Attenuation
- Atypical
- Autologous
- Avastin
- Avelumab
- Axitinib
- Baseline
- Bavencio
- Benign
- Bevacizumab
- Bias
- Bilateral
- Bilateral kidney cancer
- Bioinformatics
- Biological markers
- Biological therapy
- Biomarkers
- Biomedical
- Biopsy
- Birt- Hogg- Dube (BHD) Syndrome
- Blinded
- Blinding
- Blood urea nitrogen (BUN)
- Bone metastases
- Bone scan
- Bosniak classification of renal cysts
- Brand name
- Cabometyx
- Cabozantinib
- Cachexia
- Calorie
- Cancer
- Cancer Drugs Fund (CDF)
- Cancerous
- Cancer vaccine
- Capillary leak syndrome
- Carbohydrate
- Carcinogen
- Carcinogenesis
- Carcinoma
- Catheter
- CAT scan
- Cauterisation
- Cell proliferation
- Cells
- Cell-to-cell signalling
- Central nervous system
- Centre activation
- Checkpoint inhibitor
- Checkpoint inhibitors
- Chemical name
- Chemotherapy
- Chromophobe
- Chronic
- Circulating cancer cells
- Clear cell
- Clinical equipoise
- Clinical nurse specialist (CNS)
- Clinical oncologist
- Clinical trial
- Closed
- Collecting duct carcinoma
- Combination therapy
- Commissioning
- Committee for Medicinal Products for Human Use (CHMP)
- Complementary and alternative medicine (CAM)
- Complementary medicine
- Complete remission
- Complete response
- Compliance
- Computerised tomography (CT)
- Contralateral
- Contrast agent
- Control arm
- Coronavirus
- COVID-19
- Creatine
- Creatinine
- Cross-over trials
- Cryoablation
- Cryotherapy
- CTLA- 4 Inhibitors
- CT scan
- Cyst
- Cystoscopy
- Cytokine
- Cytoreductive nephrectomy
- Cytotoxic
- Data monitoring committee
- Debulking
- Declaration of Helsinki
- Dendritic cell
- Diagnosis
- Dialysis
- Diffuse
- Diplopia
- Disease free survival
- Disease progression
- Disease specific interval
- Double blind clinical trial
- Dysphagia
- Dysuria
- Early Access to Medicines Scheme (EAMS)
- ECOG
- Eligibility criteria
- Embolisation
- Enucleation
- Epidemiological study
- Epidural block
- Epithelial carcinoma
- Epithelial tissue
- Erythrocyte sedimentation rate (ESR)
- Erythropoietin
- Ethics committee
- European Association of Urology (EAU)
- European Medicines Agency (EMA)
- Event rate
- Everolimus
- Evidence base
- Excisional biopsy
- Exclusion criteria
- Exophytic
- Extracranial
- False-negative test result
- False-positive test result
- Familial cancer
- Fatigue
- Favourable-risk
- Fentanyl
- Fine-needle aspiration
- First-line treatment
- Five-year survival
- Food and Drug Administration (FDA)
- Fractions
- Frozen section
- Full blood count (FBC)
- Gadolinium
- Gamma irradiation
- Gamma knife surgery
- Gamma radiation
- Gene
- Generic name
- Gene therapy
- Genetic marker
- Genetics
- Genomics
- Gerota's Capsule
- Glossary
- Glutaminase inhibitor
- Good Clinical Practice (GCP)
- Grade
- Haematogenous
- Haematuria
- Haemoglobin
- Haemoptysis
- Half-life
- Hand-foot syndrome
- Hazard ratio
- Health economics
- Health technology appraisal (HTA)
- Helper T cell
- Hereditary
- Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
- High-grade
- High intensity focused ultrasound (HIFU)
- Hilar
- Histopathology
- Hospice
- Hydronephroma
- Hypercalcaemia
- Hyperplasia
- Hyperprogression
- Hypertension
- Hyperuricemia
- Hypervascular
- Hypotension
- Hypoxia
- Immune response
- Immune system
- Immunoassay
- Immunomodulating
- Immuno-oncology
- Immunotherapy
- Implantable pump
- Incisional biopsy
- Inclusion criteria
- Incremental Cost Effectiveness Ratio (ICER)
- Individual participant data (IPD) meta-analysis
- Indolent
- Inferior vena cava
- Infliximab
- Informed consent
- Infusion
- Inlyta
- Intensity-modulated radiotherapy (IMRT)
- Interferon
- Interim analysis
- Interleukin (IL 2)
- Intermediate-risk
- Intervention
- Interventional oncology
- Interventional radiology
- Intracranial
- Intravenous pyelogram (IVP)
- Intravenous urogram (IVU)
- Investigational drug
- Ipilimumab
- Jaundice
- Karnofsky index
- Keloid
- Keytruda
- Kidney cancer
- Killer cell
- Kisplyx
- Lactic Acid Dehydrogenase
- Laparoscopic nephrectomy
- Laparoscopy
- Laparotomy
- Laproscope
- Latent
- Leibovich score
- Lenvatinib
- Lesion
- Leukocyte
- Leukopenia
- Liquid biopsy
- Liver function test
- Liver metastasis
- Localised
- Locally advanced
- Low grade
- Lymph
- Lymphatic System
- Lymphatic system
- Lymph node
- Lymphocytes
- Lytic lesion
- Magnetic resonance imaging (MRI)
- Magnetic resonance spectroscopic imaging (MRSI)
- Malignant
- Malignant ascites
- Malnutrition
- Mammalian target of rapamycin (mTOR) inhibitors
- Margin
- Mean
- Mean survival time
- Median
- Medical oncologist
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Megace
- Memorial Sloan Kettering Cancer Center (MSKCC)
- Meta-analysis
- Metachronous
- Metastasectomy
- Metastasis
- Metastasise
- Methodological research
- MET kinase inhibitors
- Microbiome
- Molecular markers
- Molecular profile
- Molecular profiling
- Molecule
- Monoclonal antibody
- Morphine
- Mucinous tubular and spindle cell carcinoma
- Mucositis
- Multidisciplinary team (MDT)
- Multifocal
- Multiple technology appraisal (MTA)
- Mutation
- Mylagia
- National Health Service (NHS)
- National Institute for Health and Care Excellence (NICE)
- National Institute for Health Research (NIHR)
- Natural killer cell (NK cell)
- Nausea
- Necrosis
- NED
- Needle biopsy
- Neoadjuvant therapy
- Neoplasm
- Nephrectomy
- Nephron
- Nephron-sparing surgery
- Nephrotoxic
- Neuropathic pain
- Nexavar
- NIL per os (NPO)
- Nivolumab
- Non-steroidal anti-inflammatory drug (NSAID)
- Nuclear grade
- Objective response
- Observational study
- Oedema
- Off-label
- Oligometastatic
- Oligoprogressive
- Oncogene
- Oncologist
- Oncology
- Opdivo
- Open label trials
- Open to recruitment
- Open trial
- Opiate
- Osteonecrosis
- Outcome measures
- Overall survival
- Palinopsia
- Palliation
- Palliative care
- Palliative therapy
- Papillary
- Paracentesis
- Paraganglionoma
- Paraneoplastic syndromes
- Partial nephrectomy
- Partial response
- Pathological fracture
- Pathologist
- Patient Advocate
- Patient-controlled analgesia (PCA)
- Pazopanib
- PD-1 inhibitor
- PD-L1 inhibitor
- Pembrolizumab
- Percutaneous
- Pericardial effusion
- Peri-operative
- Peripheral neuropathy
- Phaeochromocytoma
- Phase I clinical trials
- Phase II clinical trials
- Phase III clinical trials
- Phase IV clinical trials
- Photodynamic therapy
- Physical examination
- PICC-Line
- Placebo
- Plasmapheresis
- Pleura
- Pleural cavity
- Pleural effusion
- Pleurodesis
- Polycythaemia
- Poor risk
- Port
- Positron emission tomography (PET) scan
- Postoperative
- Postural orthostatic hypotension
- Prednisone
- Primary cancer
- Primary endpoint
- Primary tumour
- Prognosis
- Prognostic factor
- Programmed cell death
- Progression
- Progression-free survival (PFS)
- Progressive disease
- Prophylaxis
- Protein kinase inhibitors
- Protocol
- Pruritus
- Pseudoprogression
- Psychosocial
- Psychosomatic
- Quality Adjusted Life Year (QALY)
- Quality of Life
- Radical nephrectomy
- Radiofrequency ablation (RFA)
- Radiologist
- Radiology
- Radiosurgery
- Radiotherapy
- Randomisation
- Randomised controlled trial (RCT)
- Rapamycin (sirolimus)
- Real world data
- Recurrence
- Red blood cell
- Regression
- Relapse
- Relative survival
- Remission
- Renal artery
- Renal capsule
- Renal cell carcinoma (RCC)
- Renal medullary carcinoma
- Renal oncocytoma
- Renal pelvis
- Renal translocation carcinoma
- Residual cancer
- Response
- Response Evaluation Criteria in Solid Tumours (RECIST)
- Response evaluation criteria in solid tumours (RECIST)
- Response rate
- Rigors
- Sarcomatoid RCC
- Sarcopenia
- SARS-CoV-2
- Savolitinib
- Scottish Medicines Consortium (SMC)
- Secondary cancer
- Secondary endpoint
- Second-line treatment
- Sedimentation rate
- Shared decision making
- Side effects
- Single technology appraisal (STA)
- Sirolimus
- Solid tumour
- Sorafenib
- Specialised services
- Stable disease
- Stage 1 kidney cancer
- Stage 2 kidney cancer
- Stage 3 kidney cancer
- Stage 4 kidney cancer
- Staging
- Stem cell
- Stereotactic radiotherapy
- Sunitinib
- Surgical oncologist
- Surrogate endpoint
- Survival rate
- Sutent
- Symptom
- Synchronous
- Systematic review
- Systemic
- Systemic treatment
- Targeted therapy
- T cells
- Tecentriq
- Telaglenastat
- Temsirolimus
- Thermoablation
- Tivozanib
- TNM staging
- Toxicity
- Trade name
- Transdermal
- Transitional cell
- Transitional cell carcinoma (TCC)
- Translational research
- Treatment arm
- Trial Management Group (TMG)
- Trial phases
- Trial set-up
- Trial Steering Committee (TSC)
- Tuberous sclerosis
- Tumour
- Tumour burden
- Tumour load
- Tumour specific antigen
- Tyrosine kinase inhibitor (TKI)
- Ultrasound scan
- Unclassified
- Urea and electrolytes (U&E)
- Ureter
- Urethra
- Uric acid
- Urologist
- Urology
- Urothelial carcinoma
- Vaccine
- Vascular endothelial growth factor (VEGF)
- Vascular endothelial growth factor (VEGF) inhibitor
- Von Hippel-Lindau (VHL) syndrome
- Votrient
- Watch and wait
- Watchful waiting
- Wedge resection
- White blood cell
- Wilm's Tumour
- X-ray
- Yervoy
- Zoledronic acid
- Zometa
